Keywords
hospital acquired infections
SARS-CoV2
COVID-19
secondary bacterial infections
multidrug resistance
anti-microbial resistance
COVID ICU
non-COVID ICU
Abstract
Introduction: Secondary bacterial infections have been reported in majority of patients hospitalized with coronavirus disease 2019 (COVID-19). A study of the antimicrobial susceptibility profiles of these bacterial strains revealed that they were multidrug resistant, demonstrating their resistance to at least three classes of antimicrobial agents including beta-lactams, fluoroquinolones and aminoglycosides. Bacterial co-infection remains as an important cause for high mortality in patients hospitalized with COVID-19.
Methods: In our study, we conducted a retrospective comparative analysis of bacterial co-infections and the antimicrobial resistance profile of bacterial isolates obtained from inpatients admitted in COVID-19 and non COVID-19 intensive care units. The goal was to obtain the etiology and antimicrobial resistance of these infections for more accurate use of antimicrobials in clinical settings. This study involved a total of 648 samples collected from 356 COVID 19 positive patients and 292 COVID19 negative patients admitted in the intensive care unit over a period of six months from May to October 2020.
Results: Among the co-infections found, maximum antimicrobial resistance was found in Acinetobacter species followed by Klebsiella species in both the ICU's. Incidence of bacterial co-infection was found to be higher in COVID 19 intensive care patients and most of these isolates were multidrug resistant strains.
Conclusion: Therefore, it is important that co-infections should not be underestimated and instead be made part of an integrated plan to limit the global burden of morbidity and mortality during the SARS-CoV-2 pandemic and beyond.
References
[2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15; 395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
[3] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28; 395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.
[4] Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Frontiers in microbiology. 2017 Jun 23; 8:1041. doi.org/10.3389/fmicb.2017.01041.
[5] Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854-887. doi: 10.1007/s00134-020-06022-5.
[6] Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH, Li YR, Liang K, Lin LK, Luo LS, Ma J, Ma LL, Peng ZY, Pan YB, Pan ZY, Ren XQ, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YG, Zhang HM, Zhao Y, Zhao MJ, Zi H, Zeng XT, Wang YY, Wang XH; , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020 Feb 6; 7(1):4. doi: 10.1186/s40779-020-0233-6.
[7] Critical CR, Medicine C, Hospital YC, Medicine AO. Chinese experts' consensus on diagnosis and treatment of severe and critical coronavirus disease 2019 (revised edition). Zhonghua wei zhong bing ji jiu yi xue. 2020 Mar; 32(3):269-74. doi: 10.3760/cma.j.cn121430-20200218-
[8] Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases of coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15):769. doi: 10.1093/cid/ciaa272
[9] Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, Zhang Y. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020 Sep 22; 9(1):153. doi: 10.1186/s13756-020-00819-1.
[10] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15; 395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.
[11] Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, Akdis CA, Gao YD. Eleven faces of coronavirus disease 2019. Allergy. 2020 Jul; 75(7):1699-1709. doi: 10.1111/all.14289.
[12] Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR Jr, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan M, Reshetnyak E, Hupert N, Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11; 382(24):2372-2374. doi: 10.1056/NEJMc2010419.
[13] Mackie TJ, Collee J. G.McCartney, Mackie & McCartney practical medical microbiology 14 th edition. New York:Churchill Livingstone,2006.
[14] Mahmoudi H. Bacterial co-infections and antibiotic resistance in patients with COVID-19. GMS Hygiene and Infection Control. 2020; 15. doi: 10.3205/dgkh000370
[15] Khurana, S., Singh, P., Sharad, N., Kiro, V.V., Rastogi, N., Lathwal, A., Malhotra, R., Trikha, A. and Mathur, P., 2021. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian journal of medical microbiology, 39(2), pp.147-153. doi: 10.1016/j.ijmmb.2020.10.014
[16] Rezasoltani S, Yadegar A, Hatami B, Aghdaei HA, Zali MR. Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR. Frontiers in microbiology. 2020;11. doi: 10.3389/fmicb.2020.590683.
[17] Lucien MA, Canarie MF, Kilgore PE, Jean-Denis G, Fénélon N, Pierre M, Cerpa M, Joseph GA, Maki G, Zervos MJ, Dely P. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. International Journal of Infectious Diseases. 2021 Mar 1; 104:250-4. https://doi.org/10.1016/j.ijid.2020.12.087
[18] Vaillancourt M, Jorth P. The unrecognized threat of secondary bacterial infections with COVID-19. Mbio. 2020 Aug 25; 11(4). DOI: 10.1128/mBio.01806-20
[19] Rawson TM, Moore LS, Castro-Sanchez E, Charani E, Davies F, Satta G, Ellington MJ, Holmes AH. COVID-19 and the potential long-term impact on antimicrobial resistance. Journal of antimicrobial chemotherapy. 2020 Jul 1;75(7):1681-4. doi.org/10.1093/jac/dkaa194.
[20] Bengoechea JA, Bamford CG. SARS‐CoV‐2, bacterial co‐infections, and AMR: the deadly trio in COVID‐19? EMBO molecular medicine. 2020 Jul 7; 12(7):e12560. doi: 10.15252/emmm.202012560.